Insilico Medicine, a Hong Kong-based clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced Wednesday that it has completed a second closing of its Series D round, led by Prosperity7 Ventures, the diversified growth fund of Aramco Ventures, bringing the total Series D financing to $95 million.